JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Hospital General de Ciudad Real
Ciudad Real, EspañaPublicaciones en colaboración con investigadores/as de Hospital General de Ciudad Real (8)
2019
-
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
European Urology, Vol. 75, Núm. 3, pp. 368-373
-
Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer
Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503
-
Real-world outcome of 173 metastatic non-clear cell renal cell carcinoma (nccrcc) cases: The experience of the center group for genitourinary tumors
Kidney Cancer, Vol. 3, Núm. 1, pp. 41-50
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2017
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
2016
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02
Annals of Oncology, Vol. 27, pp. vi277
-
Retrospective analysis of metastatic non-clear cell renal carcinoma (NCCRC): the Spanish Grupo Centro Experience
Annals of Oncology, Vol. 27, pp. vi290